 |
BioWorld-Insight-2010-04-19
Waiting to Exhale: COPD Push 'Daxas' Patience of Developers
Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: Feb. 1 - April 16, 2010
No Abstract
Waiting to Exhale: COPD Push 'Daxas' Patience of Developers
"The most bizarre we've ever seen." That's how Jefferies & Co. analyst Corey Davis described the FDA advisory panel meeting earlier this month on Daxas (roflumilast), the drug candidate for chronic obstructive pulmonary disease from Forest Laboratories Inc. and Nycomed GmbH.